The world urgently needs new drugs to replace the antimicrobial drugs that are losing effectiveness, but the incentives to invest in research are missing. A solution need not be expensive, especially when compared to the alternative: $100 trillion in lost output by 2050 and ten million deaths every year.
JAKARTA – In December, I reported the first findings of the Review on Antimicrobial Resistance, which I chair. The news wasn’t good: Resistant infections already claim more than 700,000 lives a year. Unless action is taken, antimicrobial resistance will kill ten million people a year by 2050 – more than the number of people who currently die from cancer. It will also have a cumulative cost of at least $100 trillion, more than 1.5 times today’s annual global GDP.
We are not doing nearly enough to combat this danger. The world urgently needs new drugs to replace the antibiotics, anti-malarial regimes, anti-retroviral AIDS and HIV medications, and tuberculosis treatments that are losing effectiveness. But we do not invest enough in research and development. It is critical that we find new sources of funding to support the academic researchers and small companies whose discoveries are laying the foundations for tomorrow’s medicines.
That is why I am calling on international donors – philanthropic and governmental alike – to work with the Review on Antimicrobial Resistance to create a new fund to support R&D in this important area. The fund will provide grants for blue-sky science and act as a non-profit incubator for promising discoveries. Over the coming months, the Review will be working out the details of how such a fund could operate effectively.
We hope you're enjoying Project Syndicate.
To continue reading, subscribe now.
Subscribe
Get unlimited access to PS premium content, including in-depth commentaries, book reviews, exclusive interviews, On Point, the Big Picture, the PS Archive, and our annual year-ahead magazine.
Already have an account or want to create one?
Log in
JAKARTA – In December, I reported the first findings of the Review on Antimicrobial Resistance, which I chair. The news wasn’t good: Resistant infections already claim more than 700,000 lives a year. Unless action is taken, antimicrobial resistance will kill ten million people a year by 2050 – more than the number of people who currently die from cancer. It will also have a cumulative cost of at least $100 trillion, more than 1.5 times today’s annual global GDP.
We are not doing nearly enough to combat this danger. The world urgently needs new drugs to replace the antibiotics, anti-malarial regimes, anti-retroviral AIDS and HIV medications, and tuberculosis treatments that are losing effectiveness. But we do not invest enough in research and development. It is critical that we find new sources of funding to support the academic researchers and small companies whose discoveries are laying the foundations for tomorrow’s medicines.
That is why I am calling on international donors – philanthropic and governmental alike – to work with the Review on Antimicrobial Resistance to create a new fund to support R&D in this important area. The fund will provide grants for blue-sky science and act as a non-profit incubator for promising discoveries. Over the coming months, the Review will be working out the details of how such a fund could operate effectively.
We hope you're enjoying Project Syndicate.
To continue reading, subscribe now.
Subscribe
Get unlimited access to PS premium content, including in-depth commentaries, book reviews, exclusive interviews, On Point, the Big Picture, the PS Archive, and our annual year-ahead magazine.
Already have an account or want to create one? Log in